» Articles » PMID: 6824563

Assessment of the Interaction Between Mianserin and Centrally-acting Antihypertensive Drugs

Overview
Specialty Pharmacology
Date 1983 Jan 1
PMID 6824563
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

1 The interaction between mianserin and centrally-acting antihypertensive drugs was evaluated in normal volunteers and in patients with essential hypertension receiving either clonidine or methyldopa. 2 The administration of the first dose of 20 mg mianserin to the normal volunteers was associated with a significant sedative effect and transient postural hypotension. 3 In the normal volunteers, the blood pressure responses to a single oral dose of 300 micrograms clonidine were not modified by pretreatment with mianserin. The bradycardia associated with clonidine alone, however, was significantly attenuated. 4 In the patient study, no significant changes in blood pressure control were observed, either after the first dose of 30 mg mianserin or after one and two weeks' continued treatment with mianserin. 5 There is no evidence from these studies that the addition of mianserin therapy results in a clinically significant impairment of the antihypertensive effects of clonidine or methyldopa.

Citing Articles

Neurogenic Hypertension, the Blood-Brain Barrier, and the Potential Role of Targeted Nanotherapeutics.

Lamptey R, Sun C, Layek B, Singh J Int J Mol Sci. 2023; 24(3).

PMID: 36768536 PMC: 9916775. DOI: 10.3390/ijms24032213.


Antidepressant Drugs Effects on Blood Pressure.

Calvi A, Fischetti I, Verzicco I, Belvederi Murri M, Zanetidou S, Volpi R Front Cardiovasc Med. 2021; 8:704281.

PMID: 34414219 PMC: 8370473. DOI: 10.3389/fcvm.2021.704281.


"First-dose" response to mianserin: effects of age.

Swift C, Swift M, Tiplady B Psychopharmacology (Berl). 1988; 96(2):273-6.

PMID: 3148155 DOI: 10.1007/BF00177574.

References
1.
Rand M, Rush M, Wilson J . Some observations on the inhibition of salivation by St 155 [2-(2,6-dichlorophenylamine)-2-imidazoline hydrochloride, Catapres, Catapresan]. Eur J Pharmacol. 1969; 5(2):168-72. DOI: 10.1016/0014-2999(69)90025-9. View

2.
Schmitt H . Localization of the hypotenisve effect of 2-(2-6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, Catapresan). Eur J Pharmacol. 1969; 6(1):8-12. DOI: 10.1016/0014-2999(69)90057-0. View

3.
ROBSON R, KAPLAN H, Laforce S . An investigation into the bradycardic effects of ST 155 [2-(2,6-dichlorophenylamino)-2-imidazoline HCl] in the anesthetized dog. J Pharmacol Exp Ther. 1969; 169(1):120-31. View

4.
Mitchell J, CAVANAUGH J, Arias L, OATES J . Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970; 49(8):1596-604. PMC: 322639. DOI: 10.1172/JCI106377. View

5.
Delbarre B, Schmitt H . Sedative effects of alpha-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs. Eur J Pharmacol. 1971; 13(3):356-63. DOI: 10.1016/0014-2999(71)90226-3. View